Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e13120
Abstract: e13120Background: The ROS1 rearrangement has been identified in 1%-2% of NSCLC cases, these patients would benefit from the inhibitor of crizotinib. But the resistance to crizotinib inevitably developed in the patients with ROS1+ NSCLC and… read more here.
Keywords: crizotinib; resistance crizotinib; mutational profiling; profiling chinese ... See more keywords
Genomic profiling of Chinese pancreatic adenocarcinoma and the implications for therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13515
Abstract: e13515Background: Pancreatic adenocarcinoma (PAC) remains one of the most deadly diseases with short-lived treatment responses. KRAS is the dominant driver gene in PAC, contributing to approximately 90% of PAC. Studies had revealed molecular profiles of… read more here.
Keywords: chinese pac; pancreatic adenocarcinoma; chinese pancreatic; genomic profiling ... See more keywords